Metsera Inc.’s next-generation weight-loss drug showed good tolerability with few participants dropping out of a mid-stage trial, adding to the obesity company’s appeal as two industry giants fight over who will buy it.
The study, which found the drug could lead to weight-loss on par with current market-leader Eli Lilly & Co.’s Zepbound, only had about 3% of trial participants leave the study. That’s lower than some other weight-loss drug trials, where higher rates of people stop taking medications due to side effects.